Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Ida Marie Rundgren1,2, Elisabeth Ersvær1, Aymen Bushra Ahmed3, Anita Ryningen1 and Øystein Bruserud2,3*

Abstract

Background: Induction therapy of multiple myeloma patients prior to autologous stem cell transplantation has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory drugs. We used flow cytometry to analyze total monocyte and monocyte subset (classical, intermediate and non-classical monocytes) peripheral blood levels before and following auto-transplantation for a consecutive group of myeloma patients who had received the presently used induction therapy.

Results: The patients showed normal total monocyte concentrations after induction/stem cell mobilization, but the concentrations of classical monocytes were increased compared with healthy controls. Melphalan conditioning reduced the levels of total CD14+ as well as classical and non-classical monocytes, whereas intermediate monocytes were not affected. Thus, melphalan has a non-random effect on monocyte subsets. Melphalan had a stronger effect on total and classical monocyte concentrations for those patients who had received induction therapy including immunomodulatory drugs. Total monocytes and monocyte subset concentrations decreased during the period of pancytopenia, but monocyte reconstitution occurred before hematopoietic reconstitution. However, the fractions of various monocyte subsets varied considerably between patients.

Conclusions: The total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma, but pre- and post-transplant levels of various monocyte subsets show considerable variation between patients.

Keywords: Monocytes, Multiple myeloma, Autologous stem cell transplantation

Background

Multiple myeloma is usually characterized by proliferation of abnormal plasma cells in the bone marrow and secretion of monoclonal immunoglobulin [1–3]. Autologous stem cell transplantation is an established part of early myeloma-stabilizing treatment [4, 5], and the patients usually develop a quantitative posttransplant CD4+ T cell defect that lasts for several months [6]. The posttransplant innate immune system is less well characterized, but early reconstitution of monocytes with reduced expression of HLA-DR and CD16 together with reduced cytokine production has been observed [7, 8], especially decreased release of proinflammatory cytokines (e.g. IL-6, TNF-α and IL-1β) [8].

Monocytes constitute up to 10% of total circulating peripheral blood leukocytes in healthy individuals [9]; they can differentiate into macrophages or dendritic cells...
and may also differentiate in endothelial direction [11]. Furthermore, immunomodulatory drugs (IMiDs, e.g., lenalidomide) can induce differentiation towards dendritic cells with modulation of the cytokine profile, the transcriptional regulation and the accessory cell functions [12]. Finally, based on the expression of CD14 (a cell surface co-receptor for lipopolysaccharide) and CD16 (the low affinity IgG receptor) monocytes are now divided into classical (CD14bright CD16negative), intermediate (CD14bright CD16dim) and non-classical (CD14dim CD16bright) monocytes [13–15]. Classical monocytes constitute 90% of the circulating monocytes in healthy individuals [13, 15, 16].

Monocytes seem to be involved in the development of myeloma bone disease [17–20] through the release of soluble mediators that stimulate osteoclastogenesis, and the presence of non-classical monocytes may be a potential marker for increased osteoclast precursors [18, 19]. However, monocytes are also important immunoregulatory cells, and they are important for the defense against complicating infections in myeloma patients [21–23]. Several new drugs have become available during the last decade for the treatment of multiple myeloma, and no previous studies have investigated the effects of these drugs on the levels of circulating monocyte subsets before and following auto-transplantation. In the present study, we therefore used a highly standardized methodology to characterize peripheral blood levels of monocyte subsets in auto-transplanted myeloma patients receiving pre-transplant induction treatment based on proteasome inhibitors and IMiDs.

Results

Myeloma patients show decreased concentrations of circulating total leukocytes prior to high-dose melphalan conditioning

We first compared the total leukocyte counts in peripheral blood for myeloma patients (Table 1, patients 2–18) and the healthy controls (12 males and 5 females, median age 51 years). The patients were tested immediately before high-dose melphalan conditioning, i.e. after initial induction treatment (see Table 1) followed by stem cell mobilization/collection based on cyclophosphamide plus G-CSF. At this time point they showed significantly decreased total leukocyte counts compared with the controls (Fig. 1a, p = 0.004), and patients receiving their first and second auto-transplantation showed a similar decrease. The decreased leukocyte counts were seen with both analytical methods (flow cytometry with counting beads, measurement by clinical hematology instrument), and the levels measured by these two methods were significantly correlated (Pearson correlation coefficient 0.963, p-value 0.0001). The total leukocyte levels prior to melphalan conditioning showed no association with age, induction treatment (regimen, number of cycles), response to induction treatment, circulating CD34+ cell level at the day of harvesting or duration of posttransplant neutropenia/cytopenia (data not shown).

Myeloma patients show normal peripheral blood concentrations of total monocytes but decreased levels of classical monocytes prior to high-dose melphalan

The preconditioning peripheral blood concentrations of total CD14+ monocytes did not differ between the 17 myeloma patients (Table 1, patients 2–18) and 17 healthy controls (Fig. 1a). However, classical monocyte concentrations were then slightly increased (Fig. 1a, p = 0.01) whereas we could not detect any significant differences between patients and controls for intermediate and non-classical monocytes. The three patients admitted for their second auto-transplantation showed total monocyte and monocyte subset concentrations within the range for the patients admitted for their first transplantation (Fig. 1). Thus, the effect of mobilization/conditioning on circulating monocytes is a non-random effect mainly affecting the classical monocyte subset.

The total monocyte concentrations prior to the conditioning therapy showed no association with age, induction treatment (regimen, number of cycles), response to induction treatment, circulating CD34+ cell level at the first day of harvesting or the duration of posttransplant neutropenia/cytopenia (data not shown). The same was true for classical, intermediate and non-classical monocytes except that pre-harvesting CD34+ cell levels showed significant correlations to absolute and relative levels of intermediate (r = 0.78/p = 0.001 and r = 0.75/p = 0.002, respectively) and non-classical monocytes (r = 0.63/p = 0.017 and r = 0.61/p = 0.047, respectively).

Myeloma patients are heterogeneous with regard to the preconditioning monocyte subset distribution/percentage in peripheral blood

We first compared the relative levels of circulating total CD14+ monocytes (percentage of total leukocytes) and the various monocyte subsets (percentage of total monocytes) for 18 newly diagnosed myeloma patients (Table 1, patients 1–18) and the 17 healthy controls. The preconditioning percentage of CD14+ monocytes among total leukocytes was increased for the patients; this was expected since total leukocyte levels were decreased whereas the monocyte concentration was not significantly altered before melphalan conditioning (Fig. 1b, p = 0.013). The preconditioning percentages of the classical, intermediate and non-classical monocyte subsets among CD14+ monocytes did not differ between patients and healthy controls (Fig. 1b). However, the variation range was wider for the patients both for the percentage of
total CD14+ monocytes and the three monocyte subsets. Firstly, classical monocytes constituted a majority of the CD14+ monocytes (corresponding to > 70%) both for the healthy controls and for all except five patients. We also observed wide variation ranges for the intermediate and non-classical monocyte subsets; exceptional patients showed intermediate monocyte levels exceeding 15% and non-classical monocyte levels up to 40% of the total CD14+ monocytes (Fig. 1b). Wide variations were observed both for patients admitted to their first autotransplantation and for the four patients admitted to their second transplantation. The percentages of total monocytes and monocyte subsets showed no significant associations with age, induction treatment, response to induction treatment, CD34+ cell level at the day of harvesting or time until posttransplant neutrophil/platelet reconstitution (data not shown).

The concentrations of circulating CD14+ monocytes decrease early after melphalan conditioning
We compared the peripheral blood levels of total leukocytes and CD14+ monocytes before the conditioning therapy (day −2) and 2 days later immediately before the autologous stem cell reinfusion (day 0). Ten patients

| Patient | Age (yr) | M-component | Conditioning therapy (drugs, number of cycles) | Effect of induction | CD34+ count at the time of harvesting† | Duration of cytopenia‡ |
|---------|----------|-------------|------------------------------------------------|---------------------|----------------------------------------|------------------------|
| 1       | 60–70    | IgG MM      | Second CVD                                     | 4                   | VGPR                                   | 5                      |
| 2       | 60–70    | IgG MM      | CVD                                            | 4                   | VGPR                                   | 17,120                 |
| 3       | 60–70    | IgA MM      | CVD                                            | 4                   | VGPR                                   | 32,180                 |
| 4       | 50–60    | IgG MM      | CVD                                            | 5                   | VGPR                                   | 48,635                 |
| 5       | 50–60    | IgG MM      | CVD                                            | 5                   | PR                                     | 42,285                 |
| 6       | 30–40    | LCD         | CVD (1), KRD (4)                               | 5                   | VGPR                                   | 90,950                 |
| 7       | 60–70    | IgG MM      | VTD (1), CVD (2)                               | 3                   | VGPR                                   | 218,945                |
| 8       | 60–70    | IgG MM      | CVD                                            | 4                   | VGPR                                   | 123,190                |
| 9       | 60–70    | IgA MM      | CVD                                            | 5                   | PR                                     | 37,060                 |
| 10      | 60–70    | IgG MM      | CVD                                            | 6                   | PR                                     | 5                      |
| 11      | 60–70    | IgA MM      | CVD                                            | 4                   | VGPR                                   | 32,125                 |
| 12      | 60–70    | IgA MM      | VRD                                            | 4                   | VGPR                                   | 5                      |
| 13      | 60–70    | LCD-L       | CVD                                            | 4                   | VGPR                                   | 60,410                 |
| 14      | 60–70    | IgG MM      | CVD, VTD, VD (3)                               | 5                   | VGPR                                   | 132,000                |
| 15      | 60–70    | IgG MM      | VCD                                            | 4                   | PR                                     | 27,690                 |
| 16      | 60–70    | LCD-K       | RD                                             | 4                   | VGPR                                   | 185,800                |
| 17      | 60–70    | IgA-MM MM   | CVD                                            | 4                   | VGPR                                   | 36,010                 |
| 18      | 60–70    | LCD-L       | CVD (4 before and 2 after harvesting)          | 6                   | VGPR                                   | 27,690                 |
| 19      | 60–70    | IgG MM      | CVD                                            | 4                   | VGPR                                   | 5                      |
| 20      | 50–60    | Amyloid-MM IgG-L | CVD (3), VTD (1) | 4 | VGPR | 185,800 |
| 21      | 40–50    | IgG MM      | CVD (4 before harvesting), VTD (2 after), RD (2 after) | 8 | VGPR | 56,380 |
| 22      | 50–60    | LCD-L       | CVD                                            | 4                   | PR                                     | 7                      |
| 23      | 50–60    | IgG MM      | CVD                                            | 6                   | PR                                     | 5                      |
| 24      | 50–60    | LCD-L       | CVD                                            | 4                   | VGPR                                   | 74,800                 |
| 25      | 60–70    | LCD-K       | CVD                                            | 4                   | PR                                     | 3                      |

Abbreviations: CVD Cyclophosphamide, bortezomib (Velcade®), dexamethasone, LCD Light chain disease type lambda (L) or kappa (K), MM Multiple myeloma, PR Partial response, RD Lenalidomide (Revlemide®) plus dexamethasone, VGPR Very good partial response, VRD Bortezomib, lenalidomide (Revlemide®), dexamethasone, VTD Bortezomib (Velcade®), thalidomide, dexamethasone

† Patients undergoing their second auto-transplantation are indicated; the stem cell graft was the same as for the first transplantation for all these patients

‡ The peripheral blood concentration of CD34+ cells on the (first) day of harvesting is given; the level is expressed as × 10^3 cells/mL

§ Neutropenia was defined as the time from the first day of neutrophil peripheral blood concentration ≤ 0.2 × 10^9/L until the first of three consecutive days with neutrophils exceeding 0.2 × 10^9/L or alternatively the first day with neutrophil counts > 10 × 10^9/L. The duration of thrombocytopenia was defined as the number of days from the first day of peripheral blood thrombocyte counts below 20 × 10^9/L until the first day with thrombocyte count above 20 × 10^9/L without thrombocyte transfusion

The age of patients are grouped
were available for this paired comparison (Table 1, patients 7–9, 11–17), and total leukocyte levels were not altered 2 days after the melphalan infusion (i.e. immediately before transplantation, see Fig. 2a). In contrast, the concentrations of circulating monocytes were significantly decreased 2 days after the conditioning, and a similar decrease was observed when total monocyte levels were analyzed by clinical hematology instrument (data not shown) and when using whole-blood staining for flow cytometric analysis of CD14+ monocytes (Fig. 2b). A comparable decrease was seen for patients receiving their first and the second auto-transplantation, but neutrophil levels were increased for many patients (see below) so that total leukocyte levels were not significantly altered.

We finally compared the levels of circulating neutrophils, total lymphocytes and thrombocytes (estimated by clinical hematology instrument) immediately before and 2 days after melphalan conditioning (Table 1, patients 7–9, 11–17). The neutrophil levels 2 days after melphalan were slightly increased (median level 3.6 versus 4.9 × 10⁹/L, \( p = 0.06 \)), whereas lymphocyte (median level 1.0 versus 0.2 × 10⁹/L, \( p = 0.002 \)) and thrombocyte levels (median levels 225 versus 177 × 10⁹/L, \( p = 0.002 \)) were significantly decreased similar to the monocyte levels.

**Melphalan conditioning causes an early decrease in the percentages of circulating classical and non-classical monocytes whereas the levels of the intermediate subset are not altered**

We compared the peripheral blood percentages of classical, intermediate and non-classical monocytes at day –2 pre-transplant (i.e. before conditioning) and day 0 (i.e. before stem cell transplantation) for 10 patients (Fig. 2c-e; Table 1 patients 7–9, 11–17). The concentrations of all three monocyte subsets were decreased for most patients 2 days after the conditioning, but the difference reached statistical significance only for the classical (Wilcoxon’s test for paired samples; \( p = 0.002 \)) and non-classical subsets (\( p = 0.0039 \)). Thus, melphalan conditioning has a non-random early effect on circulating monocyte subsets. However, we observed a wide variation in the percentage of the various monocyte subsets among total CD14+ monocytes in preconditioning samples (Fig. 1), and wide variations persisted after conditioning both for the classical (variation range 41–93%), intermediate (2–48%) and non-classical (2–51%) monocyte subsets.

The early effect of melphalan conditioning on monocyte concentrations differs between patients receiving induction treatment with or without immunomodulatory drugs

IMiDs can alter the monocyte phenotype [24], and we therefore compared the effect of the melphalan conditioning for patients receiving induction treatment with or without IMiDs (i.e. thalidomide, lenalidomide, pomalidomide). A total of 13 patients were included in this analysis. At day 0 (the day of transplantation) patients receiving induction treatment including IMiDs showed decreased concentrations of circulating total monocytes (median level 0.0023 × 10⁹/L with range 0.001–0.01 versus 0.0061 × 10⁹/L with range 0.003–0.03; \( p = 0.045 \)) and classical monocytes (median 0.0022 × 10⁹/L with range 0.001–0.010 versus 0.0057 × 10⁹/L with range 0.0003–0.016; \( p = 0.046 \)) compared with patients receiving induction treatment without these drugs). Furthermore, the absolute and relative levels of total monocytes and the various monocyte subsets 2 days after the conditioning therapy (i.e. on day 0, the day of transplantation) showed no association with age, response to induction treatment or levels of circulating CD34+ cells at the first day of harvesting (data not shown). Finally, the day 0 pretransplant levels of circulating neutrophils, total lymphocytes and thrombocytes did not differ between patients that had received induction therapy with and without IMiDs (data not shown). Thus, the IMiDs seem to have a non-random effect on the various monocyte subsets that becomes detectable after the melphalan infusion.

**The peripheral blood concentrations of all three monocyte subsets show a further decrease during the period of severe neutropenia**

We investigated the peripheral blood concentrations of the three monocyte subsets during the period of severe neutropenia for 8 myeloma patients (Table 1 patients 13, 14, 16, 17, 21–24); for five of these patients we could compare the levels immediately before stem cell reinfusion with the levels during severe cytopenia (patients 13, 14, 16, 17, 21). As expected the concentrations of all three monocyte subsets, especially the classical and intermediate subsets, decreased to low levels during cytopenia (Fig. 2). In contrast, the relative levels (i.e. percentage among total CD14+ monocytes) varied during pancytopenia when tested 6–8 days after stem cell reinfusion. All patients showed < 5% intermediate monocytes, whereas classical monocyte levels varied between 8 and 92% (median 62%) and non-classical monocytes also showed a considerable variation (median 18%, range 3–57%).

**Auto-transplanted myeloma patients show expected early hematological reconstitution**

The levels of circulating total leukocytes, neutrophils and thrombocytes were measured by clinical hematology instrument for all our patients. Neutrophil reconstitution was defined as the first of 3 days with neutrophils above 0.2 × 10⁹/L. The median time from first day of
Fig. 1 (See legend on next page.)
neutropenia (i.e. first day with neutrophils \( \leq 0.2 \times 10^9/L \)) until neutrophil reconstitution was 4 days (range 2–9 days). Furthermore, thrombocyte reconstitution was defined as the first out of three consecutive days with thrombocyte counts above \( 20 \times 10^9/L \) in transfusion-independent patients. The median duration of thrombocytopenia (i.e. thrombocyte levels below \( 20 \times 10^9/L \)) was 4 days (range 1–6 days). Finally, time to neutrophil/thrombocyte reconstitution did not differ between patients receiving their first or second auto-transplantation and showed no significant associations with preconditioning (i.e. day – 2) or pre-transplant (i.e. day 0) total monocyte levels.

Auto-transplanted myeloma patients show early monocyte reconstitution

The absolute levels of total monocytes were followed daily during the period of early hematological reconstitution for 24 consecutive patients. The median time from transplantation until the monocyte levels exceeded the lower normal limit (0.04 – 0.78 \( \times 10^9/L \)) was 10 days; the median monocyte level was then 0.23 – 0.78 \( \times 10^9/L \) (range 0.05 – 0.78 \( \times 10^9/L \)). The neutrophil levels at the first day of monocyte normalization were generally below the lower normal limit (median \( 0.5 \times 10^9/L \), range 0.1 – 3.8 \( \times 10^9/L \)), i.e. for 18 patients the neutrophil levels were still below the lower normal limit. All patients still had severe thrombocytopenia (median \( 29 \times 10^9/L \), range 13 – 38 \( \times 10^9/L \)) at the first day of monocyte normalization. Finally, there was no significant association between preconditioning or pre-transplant total monocyte levels and time to normalized circulating monocyte levels, and monocyte normalization did not differ for patients receiving induction treatment with or without IMiDs (data not shown).

We compared the absolute and relative levels of various monocyte subsets at day +10/+12 posttransplant with the corresponding preconditioning levels (day – 2); paired samples were then available only for eight patients (Fig. 3; Table 1 patients 14, 16, 17, 21–25). This posttransplant time point corresponds to the initial neutrophil reconstitution, but the neutrophil levels were still below the lower normal limit for six of the eight patients (median level 0.7 \( \times 10^9/L \), range 0.2 – 6.8 \( \times 10^9/L \)). The thrombocyte counts for all patients (median \( 30 \times 10^9/L \), range 20 – 52 \( \times 10^9/L \)) were also below the lower normal limit. However, even at this early time point only 10 – 12 days post-transplant most patients showed normalized absolute (concentration) and relative (percentage) levels of total CD14+ monocytes as well as the three monocyte subsets within the pre-transplant variation range.

One of our collaborating local hospitals only investigated peripheral blood neutrophil but not monocyte counts at the out-patient evaluations; for this reason peripheral blood monocyte counts were only available at later time points for 15 patients. The total monocyte count (normal range 0.04 – 1.30 \( \times 10^9/L \)) was tested early after neutrophil and platelet reconstitution, and at this time point (median time 14 days posttransplant, range 14 – 16) nine patients showed normal and six patients showed increased counts (median 0.95 \( \times 10^9/L \), range 0.40 – 2.1 \( \times 10^9/L \)). The total monocyte counts tested at a later time point (median 30 days posttransplant, range 27 – 39 days) showed increased levels for a minority of four patients (median level 0.97 \( \times 10^9/L \), range 0.20 – 1.78 \( \times 10^9/L \)).

Most patients show disease stabilization lasting at least 2 years after the first transplantation

The posttransplant observation time for patients receiving their first auto-transplantation was 27 – 36 months (median 32 months). Five patients had disease progression less than 2 years post-transplant, one patient was lost from follow-up and all other patients remained in plateau phase during follow-up. Progression-free survival less than 2 years showed no association with preconditioning (\( n = 16 \)) or pretransplant (\( n = 18 \)) total monocyte or monocyte subset levels or with posttransplant time to normalized total monocyte levels (\( n = 24 \); data not shown).

Discussion

Autologous stem cell transplantation is widely used in the treatment of younger myeloma patients up to 70
Fig. 2: Absolute numbers of leukocytes, CD14+ monocytes, classical monocytes (CD14bright CD16negative), intermediate monocytes (CD14bright CD16dim), and non-classical monocytes (CD14dim CD16bright) over time post-ASCT.

- **A** Absolute numbers of leukocytes
- **B** Absolute numbers of CD14+ monocytes
- **C** Absolute numbers of classical monocytes (CD14bright CD16negative)
- **D** Absolute numbers of intermediate monocytes (CD14bright CD16dim)
- **E** Absolute numbers of non-classical monocytes (CD14dim CD16bright)

Legend: (p = 0.004) (p = 0.03) (p = 0.002)
years of age [25]. The pre-transplant conditioning therapy has direct anti-leukemic effects, but previous studies suggest that immune-mediated anti-myeloma activity may also contribute to the effect of this therapy [26–28].

The lymphoid reconstitution has been investigated in previous studies [29], but the monocytes are less well characterized and for many of the previous studies the induction treatment included conventional cytotoxic drugs and not proteasome inhibitors or IMiDs. In the present study, we investigated the levels of circulating total monocytes and monocyte subsets in auto-transplanted myeloma patients. Although our study is relatively small, we observed that the pre-transplant induction and stem cell mobilization by cyclophosphamide plus G-CSF seemed to have only a minor effect on the preconditioning monocyte levels even though the concentration of total circulating leukocytes was decreased compared with the healthy controls.

Our present observations will probably not only depend on the use of IMiDs and proteasome inhibitors in the induction treatment but on the overall clinical and biological context of our patients. One should emphasize that the use of cyclophosphamide in stem cell mobilization will probably influence our results. The same may be true for our use of posttransplant G-CSF therapy, e.g. through its effects on systemic metabolic regulation that influence the metabolic environment of regenerating hematopoietic and immunocompetent cells [30]. Furthermore, studies in healthy donors show that G-CSF has a mobilizing effect on many different immunocompetent cells, including monocytes [31, 32]. These effects differ between healthy donors; they will also influence the levels of immunocompetent cells in the stem cell grafts and possibly also outcome in allotransplant recipients. To the best of our knowledge it is not known whether similar differences exist for auto-transplanted myeloma patients, and unfortunately we do not have information about graft levels of various monocyte subsets for our patients.

We analyzed the total number of monocytes by two different methodological approaches, i.e. by using a hemocytometer and by using flow cytometry to estimate the levels of CD14+ total monocytes. Both these analyses showed that the preconditioning patient levels did not differ from healthy controls, whereas the levels 2 days after the conditioning (i.e. immediately before stem cell reinfusion) were decreased compared with the preconditioning levels. However, the levels of CD14+ monocytes were lower than the monocyte levels estimated in the alternative assays, and this difference is probably due to a random loss of cells during the washing steps.

Our studies included all except one patient from a defined geographic area and during a defined time period; for this reason it should be regarded as a population-based study. We could not investigate all patients at every time point during the treatment. However, we would emphasize that this was due to practical reasons such as transfer of patients to their local hospital or long traveling distance from their home to the transplantation center; it was not because of the disease, the treatment or development of complications. Leukocyte levels show diurnal variations [33–36], and for this reason we sampled the patients only in the morning, and shipment of samples or analysis of cryopreserved cells was not possible due to our standardized methods for handling of the samples [37].

Our present study showed that the preconditioning patient levels did not differ from healthy controls, i.e. the myeloma disease itself, the induction treatment and the stem cell mobilization by cyclophosphamide plus G-CSF have only minor effects on monocytes except for a slight increase of classical monocytes. In contrast, the melphalan conditioning seemed to have a nonrandom effect of the monocyte subsets before an early reconstitution of all three subsets was observed. However, it should be emphasized that there is a wide variation between patients with regard to the effects of the conditioning therapy. A short duration of this monocytopenia is also suggested by previous studies [7, 8], but our study is the first to suggest that this is true also for patients receiving IMiD- or proteasome inhibitor-based induction therapy and for different monocyte subsets. Furthermore, the studies by Callander et al. [38] suggest that even though monocyte levels are normalized at day 100 posttransplant, the levels of total CD14+ and CD14+CD16low/neg classical monocytes are then associated with prolonged progression-free survival after auto-transplantation. Thus, taken together these studies show that monocyte reconstitution occurs early (according to our study very early) after auto-transplantation, but
despite this normalization there is still a relatively wide variation between patients and this heterogeneity in monocyte (subset) levels seems to persist until day 100 posttransplant and may even have a prognostic impact. The antimyeloma effect of posttransplant monocyte targeting may therefore vary between patients and depend on the monocyte subset profile. IL6 is regarded as a possible target in multiple myeloma [39]; monocytes constitute a subset of the bone marrow stromal cells that are regarded as important regulators of both normal and malignant hematopoietic cells [16, 40]. IL6 is released by monocytes, especially classical monocytes, in response to ligation of various Toll-like receptors, and therapeutic targeting of IL6/monocytes may therefore be most effective for those patients with high levels of classical monocytes.

Most of our patients received only 3 or 4 induction cycles before stem cell transplantation, whereas 6 cycles are now often recommended, especially for patients who have not received a complete remission [25, 41, 42]. Alternative induction cycles have also been used in other studies [33, 41, 42], and future studies have to clarify whether our present results are representative also for patients receiving additional cycles or alternative induction treatment.

Fig. 3 The peripheral blood concentrations (a, upper part, n = 6) and percentages (b, lower part, n = 7) of total CD14+ monocytes and classical, intermediate and non-classical monocyte subsets in auto-transplanted myeloma patients. Monocyte levels were estimated by flow cytometry. We investigated the levels for a total of eight patients (Table 1, patients 15, 17, 18, 22–24) during initial hematopoietic and immunological reconstitution (tested 10–12 days posttransplant) when the patients showed increasing neutrophils > 0.2 \times 10^9/L and thrombocyte transfusion independence). Horizontal lines indicate median values after 10–12 days. The shaded parts of each figure indicate the variation range of the corresponding peripheral blood levels tested 2 days pre-transplant (referred to as day –2), i.e. immediately before high-dose melphalan conditioning therapy. Black symbols represent patients receiving their first auto-transplant, open symbols represent patients receiving their second auto-transplantation.
Our comparison of induction treatments with and without IMiDs suggests that the post-conditioning monocyte concentrations are influenced by the previous use of immunomodulatory drugs in the induction therapy, whereas the capacity of stem cell mobilization and response to the induction therapy are less important. However, G-CSF responsiveness (i.e., CD34+ cell mobilization) was associated with the levels of intermediate and non-classical monocytes before conditioning therapy.

Previous studies have shown that early posttransplant lymphoid reconstitution is associated with a favorable prognosis of auto-transplanted myeloma patients [26–29]. More recent studies suggest that this effect may be due to early NK cell reconstitution [29]. Even though monocytes have important immunoregulatory functions, the previous studies have not investigated whether the early monocytic reconstitution is required for the prognostic impact of early lymphoid reconstitution. A recent study of allotransplant recipients suggests that monocytes can mediate anti-myeloma effects [43], and monocytes derived from auto-transplanted patients may even be used for immunotherapy due to their presentation of myeloma-associated peptides to the adaptive immune system [44]. Our present studies thus suggest that a close to normal monocyte system is present in myeloma patients even early after auto-transplantation and may then be an immunotherapeutic target.

Monocytes and macrophages are important members of the bone marrow stem cell niches that support both normal and malignant hematopoiesis [40]. IMiDs can alter the differentiation of monocytes [24], and we therefore investigated whether the use of such drugs for induction therapy was associated with an altered balance between monocyte subsets later during treatment or with other differences in hematopoietic reconstitution between patients. Our present study showed that the type of induction therapy actually has an influence on monocytes/monocyte subsets, but this difference was only detected after additional melphalan therapy in pre-transplantation (Day 0) samples.

The observation time for our patients was relatively short (27–35 months) for our patients that received their first auto-transplantation and a majority of them were still in a plateau phase. We could not detect any associations between time to progression (i.e., progression before 2 years posttransplant) and monocyte subset levels/reconstitution. However, these data should be interpreted with great care because the patient cohort is relatively small for such analyses and the observation time is short and patients with early relapse are few.

Conclusions
Although our study is relatively small, we observed that the total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma. However, the levels of various monocyte subsets show considerable variation between patients. Clinical studies including larger number of patients and a longer observation time are needed to clarify whether these differences are associated with overall survival, time to relapse and/or frequencies of severe infections.

Methods
Aim, design, characteristics of myeloma patients and healthy controls
Proteasomal inhibitors and IMiDs are now commonly used in induction treatment of young and fit myeloma patients prior to stem cell harvesting and auto-transplantation. These drugs may thereby influence the pretransplant immunological status of the patients and the immunocompetent cells in the stem cell graft. The aim of our present study was therefore to investigate the preconditioning status of the monocyte system in myeloma patients treated with induction chemotherapy based on IMiDs or proteasomal inhibitors, and to characterize the monocyte subset levels in autotransplanted patients during the early posttransplant period until hematological reconstitution.

Our hospital is the only center for stem cell transplantation in a defined geographical area of Norway (Health Region III), and our patients represent all myeloma patients except one receiving autologous stem cell transplantation in this area during an 8 months period. Our study should therefore be regarded as a population-based study of unselected patients.

The diagnosis of multiple myeloma was based on generally accepted criteria [1, 45], and induction therapy was initiated in accordance with generally accepted international guidelines [45, 46]. The patient characteristics are presented in Table 1. All patients received premobilization therapy including either a proteasome inhibitor or an IMiD; this induction treatment was followed by stem cell mobilization using cyclophosphamide plus G-CSF [47, 48]. The stem cell grafts were cryopreserved in 5% dimethyl sulfoxide and stored in liquid nitrogen until reinfusion [49, 50]. All patients were transplanted with at least 6 × 10⁶ CD34+ cells per kilo body weight, and the median time from start of induction to transplantation was 16 weeks (range 13–28 weeks). For patients receiving their first autotransplantation the grafts had been stored for 3–5 weeks, whereas for those patients receiving their second transplantation the grafts were stored for at least 2 years. All patients received conditioning therapy with melphalan (Fresenius Kabi, Oslo, Norway), 200 mg/m² administered as an intravenous infusion 2 days before stem cell reinfusion. They received G-CSF 5 μg/kg from day +4 post-transplant until stable neutrophil recovery, i.e. peripheral
blood neutrophil levels above $0.2 \times 10^9/L$ for three consecutive days or exceeding $10 \times 10^9/L$.

The normal controls were healthy blood donors; in accordance with the approved routines at the Blood Bank, Haukeland University Hospital peripheral venous blood samples for medical research were donated after written informed consent.

**Blood sampling**

Blood samples were drawn in ACD-A (9 mL, #248368, BD Vacutainer, San Jose, CA, USA) blood sampling vacuum tubes. We collected the first patient sample immediately before melphalan conditioning (day −2). The second sample was collected 2 days later immediately before reinfusion of the peripheral blood stem cell graft (day 0). The third sample was collected on day +6 post-transplant when patients had severe neutropenia (peripheral blood neutrophil counts below $<0.2 \times 10^9/L$) and thrombocytopenia. The last sample was collected on the first or second day with peripheral blood neutrophil counts exceeding $0.2 \times 10^9/L$ (10–12 days post-transplant). The control samples were derived from 17 healthy blood donors (5 females and 12 males, median age 51 years with range 22–82 years). All samples were processed at room temperature within 120 min. All samples were collected between 08:00 and 10:00 am. It was not possible to get samples from all patients at all four time points; this was due to either transfer of the local hospitals after stem cell reinfusion or the patient was not available for sampling at the indicated time in the morning.

**Flow cytometric analysis**

Four mL of ACD-A (9, #248368, BD Vacutainer) anticoagulated whole blood and 46 mL of lysing buffer (#55589, BD Biosciences) were mixed and incubated for 15 min at room temperature. Subsequently, leukocytes were collected by centrifugation (400×g, 5 min, room temperature) and thereafter washed in phosphate-buffered saline with 1% Bovine Serum Albumin (BSA, Bovine Serum Albumin Fraction V #10735086001, Sigma-Aldrich/Merc KGaA, Darmstadt, Germany). The cells were reconstituted in 200 μL 1% BSA/PBS with 10% immunoglobulin solution (Octagam 100 mg/mL, Octapharma, Lachen, Switzerland). The following mouse anti-human antibodies were included in the antibody panel (all from BD Biosciences, San Jose, CA, US): CD14 Alexa 488 (Clone M5E2), CD56 Alexa 647 (Clone B159), CD16 PerCpCy^5–5 (Clone 3G8), CD45 V500 (Clone HI30), CD11b V540 (Clone ICRF44 (44)) and HLA-DR PE (Clone G46–6). The staining procedure and gating strategy for identification of monocytes and monocyte subsets has been described in detail in a previous methodological article [37].

All samples were analyzed by a 10-parameter BD FACS Verse flow cytometer equipped with 404, 488 and 640 nm lasers. We used BD FACSuite™ CS&T Research Beads (#650621, BD Biosciences, San Jose, CA, USA) for regular quality control of the instrument, single-stained compensation bead samples (#552843, BD Biosciences) for compensation and unstained samples as gating controls. At least 5000 monocytes were analyzed for each sample (based on SSC/FSC properties). We used counting beads (Count Bright Absolute Counting beads™, #C36950, Invitrogen™, Thermo Fischer Scientific, Waltham, MA USA) when estimating the concentrations of monocytes/monocyte subsets. Flowjo software (Tree Star, Inc., OR, USA) was used for analysis of the results.

**Analysis of total leukocytes, neutrophils, monocytes and thrombocytes in peripheral blood**

Analyses of peripheral blood levels of total leukocytes and total monocytes were performed by using accredited clinical hematology instrument (Laboratory for Clinical Biochemistry and Hematology at Haukeland University Hospital).

**Statistical analyses**

We applied IBM SSP statistics 23 for all statistical analyses. The Wilcoxon’s rank sum test and the Wilcoxon’s test for paired samples were used for comparison of different groups and for comparison of paired observations, respectively. The Pearson’s test was used for correlation analyses. Differences were regarded as statistically significant when $p$-values were below 0.05.

**Abbreviation**

IMiDs: Immune modulatory drugs

**Acknowledgments**

We are grateful to the staff at the Department of Medicine (Section for Hematology) and The Blood Bank at Haukeland University Hospital for providing patient samples and controls samples, respectively.

**Authors’ contributions**

IMR performed the experiments. ABA and ØB recruited patients and provided clinical data. IMR, AR, EE and ØB designed the study. IMR, AR, EE, ABA and ØB wrote the article. All authors read and approved the final manuscript.

**Funding**

This research was funded by the Norwegian Cancer Society (grant number 100933 and 182609), Helse-Vest (grant number 911946, 912051 and 912178), University of Bergen and Western Norway University of Applied Sciences. None of the funders had a role in designing the study, collection, analysis or interpretation of data, or in the writing of this manuscript.

**Availability of data and materials**

The data sets used and analyzed during the study are available from the corresponding author on request.

**Ethics approval and consent to participate**

The study was conducted according to the Declaration of Helsinki. Collection of patient samples and the use of these samples in the present study were approved by the Regional Ethics Committee. Samples were collected and...
stored after written informed consent (REK Vest 2015/1759), and the use of biological material and the present project was also approved by the committee (REF Vest 2017/305, 2013/102). The normal controls were healthy blood donors; in accordance with the approved routines at the Blood Bank, Haukeland University Hospital, peripheral venous blood samples for medical research were donated after written informed consent.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Biomedical Laboratory Scientist Education and Chemical Engineering Faculty of Engineering and Natural Sciences, Western Norway University of Applied Sciences, Bergen, Norway. 2Department of Clinical Science, University of Bergen, Bergen, Norway. 3Section for Hematology, Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway.

Received: 17 January 2019 Accepted: 22 October 2019

Published online: 08 November 2019

References
1. Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
2. Kyle RA, Gertz MA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(9):1211–33.
3. Drayson M, Tang LX, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900–2. https://doi.org/10.1182/blood.V97.9.2900.
4. Vincent Rajkumar S. Multiple myeloma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(10):999–1009. https://doi.org/10.1002/ajh.23810.
5. Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101–19. https://doi.org/10.1016/j.mayocp.2015.11.007.
6. Guillaume T, Rubinstein DB, et al. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood. 1998;92(5):1471–90.
7. Wichert S, Pettersson A, et al. Phenotype, function, and differentiation potential of human monocyte subsets. PLoS One. 2017;12(4):e0176460. https://doi.org/10.1371/journal.pone.0176460.
8. Statland BE, Winkel P, et al. Evaluation of Biologic Sources of Variation of Leukocyte Counts and Other Hematologic Quantities Using Very Precise Automated Analyzers. Am J Clin Pathol. 1978;69(1):48–54.
9. Carden M, Tang LX, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Exp Hematol. 2016;44(5):342–51.e5. https://doi.org/10.1016/j.exphem.2016.01.002.
10. Rondorf S, Diefenbach A, et al. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma. Exp Hematol. 2016;44(5):342–51.e5. https://doi.org/10.1016/j.exphem.2016.01.002.
11. Hatfield KJ, Melve GK, et al. CD14+CD16+ monocytes are a potential cytological marker of circulating monocytes and their deployment to inflammatory sites. Science. 2009;325(5940):612–15. https://doi.org/10.1126/science.1175202.
12. Impola U, Larjo A, et al. Graft Immune Cell Composition Associates with Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with AML. Front Immunol. 2016;7:523. https://doi.org/10.3389/fimmu.2016.00523.
13. Shamsa E, Tapp LD, et al. The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. Eur J Clin Invest. 2012;42(8):852–9. https://doi.org/10.1111/j.1365-2362.2012.02656.x.
14. Smith LA, Solheim RB, et al. Rhythms in human bone marrow and blood cells. Chronobiol Int. 2002;19(1):1–27. https://doi.org/10.1080/1042019031000077089.
37. Rundgren IM, Bruserud O, et al. Standardization of sampling and sample preparation for analysis of human monocyte subsets in peripheral blood. J Immunol Methods. 2018;461:53–62. https://doi.org/10.1016/j.jim.2018.06.003.

38. Callander NS, Rathouz PJ, et al. Recovery of Natural Killer Cells and Monocyte Subsets Following Autologous Peripheral Blood Stem Cell Transplantation Predicts Longer Progression-Free Survival Among Multiple Myeloma Patients. Blood. 2013;122(21):12126.

39. Rosean TR, Tompkins VS, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59(1–3):188–202. https://doi.org/10.1007/s12026-014-8528-x.

40. Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208(3):421–8. https://doi.org/10.1084/jem.20110132.

41. Fleming S, Harrison SJ, et al. The Choice of Multiple Myeloma Induction Therapy Affects the Frequency and Severity of Oral Mucositis After Melphalan-Based Autologous Stem Cell Transplantation. J Natl Compr Canc Net. 2013;11(1):19–28. https://doi.org/10.6004/jnccn.2013.0005.

42. Lonial S, San Miguel JF. Induction Therapy for Newly Diagnosed Multiple Myeloma. J Natl Compr Canc Net. 2013;11(1):19–28. https://doi.org/10.6004/jnccn.2013.0005.

43. Dhalak B, Brazauskas R, et al. Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2015;21(2):5163–54. https://doi.org/10.1016/j.jbmt.2014.11.239.

44. Vasileiou S, Baltadakis I, et al. Ex Vivo Induction of Multiple Myeloma-specific Immune Responses by Monocyte-derived Dendritic Cells Following Stimulation by Whole-tumor Antigen of Autologous Myeloma Cells. J Immunother. 2017;40(7):253–64.

45. Landgren O, Rajkumar SV. New developments in diagnosis, prognosis, and assessment of response in multiple myeloma. Clin Cancer Res. 2016;22(22):5428–33. https://doi.org/10.1158/1078-0432.Ccr-16-0866.

46. Chantry A, Kazmi M, et al. Guidelines for the use of imaging in the management of patients with myeloma. Brit J Haematol. 2017;178(3):380–93. https://doi.org/10.1111/bjh.14827.

47. Mosevoll KA, Akkok CA, et al. Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 2013;15(7):850–60. https://doi.org/10.1016/j.jcyt.2013.02.008.

48. Akkok CA, Hervig T, et al. Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 2011;13(10):1259–68. https://doi.org/10.3109/14653249.2011.605117.

49. Bakken AM, Bruserud O, et al. No differences in colony formation of peripheral blood stem cells frozen with 5% or 10% dimethyl sulfoxide. J Hematother Stem Cell. 2003;12(3):351–8. https://doi.org/10.1089/152581603322023089.

50. Abrahamsen JF, Rusten L, et al. Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide. Transfusion. 2004;44(5):785–9. https://doi.org/10.1111/j.1537-2995.2004.03336.x.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.